Reporting Date | Major Shareholder Name | Shares Held | Market Value | Change in Shares | Ownership |
---|---|---|---|---|---|
05/10/2024 | KEPOS CAPITAL LP | 334,600 | $4,000 | 0.00% | 27.28% |
05/06/2024 | WARBERG ASSET MANAGEMENT LLC | 289,868 | $3,594 | 0.00% | 23.63% |
05/15/2024 | ARMISTICE CAPITAL, LLC | 50,000 | $615 | -95.00% | 4.08% |
05/15/2024 | CITADEL ADVISORS LLC | 13,204 | $162 | 0.76% | 1.08% |
A. During the previous two years, 5 institutional investors and hedge funds held shares of Pasithea Therapeutics Corp.. The most heavily invested institutionals were:
Kepos Capital LP: 334,600
Warberg Asset Management LLC: 289,868
ARMISTICE CAPITAL, LLC: 50,000
CITADEL ADVISORS LLC: 13,204
CITADEL ADVISORS LLC: 13,104
A. 56.06% of Pasithea Therapeutics Corp. stock is owned by institutional investors.
A. Institutional investors have bought a total of 700,776 shares in the last 24 months. This purchase volume represents approximately $7,779 in transactions.